GSK: positive phase III data in COPD
(CercleFinance.com) - On Friday, GSK published new positive Phase III data for Nucala in the treatment of chronic obstructive pulmonary disease (COPD), a chronic inflammatory disease.
The trial, involving 806 patients followed for one to two years, met its primary endpoint by showing a 'statistically and clinically significant' reduction in disease-related exacerbations compared to placebo.
Chronic obstructive pulmonary disease (COPD) is an obstruction of the airways caused by an inflammatory response to inhaled toxic substances, often cigarette smoke.
Nucala, a monoclonal antibody, blocks a specific protein called interleukin-5 (IL-5), thereby reducing the overproduction of eosinophils, a type of white blood cell, in the lungs.
The drug is already approved in many markets as an adjunctive therapy for the maintenance treatment of severe asthma.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The trial, involving 806 patients followed for one to two years, met its primary endpoint by showing a 'statistically and clinically significant' reduction in disease-related exacerbations compared to placebo.
Chronic obstructive pulmonary disease (COPD) is an obstruction of the airways caused by an inflammatory response to inhaled toxic substances, often cigarette smoke.
Nucala, a monoclonal antibody, blocks a specific protein called interleukin-5 (IL-5), thereby reducing the overproduction of eosinophils, a type of white blood cell, in the lungs.
The drug is already approved in many markets as an adjunctive therapy for the maintenance treatment of severe asthma.
Copyright (c) 2024 CercleFinance.com. All rights reserved.